Among sex steroids, especially estrogen metabolism has been considered to play a role in the function and pathology of human veins. We investigated the expression and activity of the estrogen-producing enzyme aromatase and estrogen receptor (ER) in human vena cava to assess possible in situ biosynthesis of estrogens and their modes of action. We first examined aromatase expression by immunohistochemistry in human inferior vena cava obtained from 29 autopsy cases (11 males, 18 females, 63.6±3.0 years old). We then semiquantitated the level of aromatase mRNA by reverse transcriptase-polymerase chain reaction in 24 cases and aromatase activity by 3H-water assay in 15 cases to examine whether or not and in which cell types aromatase was expressed. We also studied alternative use of multiple exon is of its gene and immunolocalization of 17,0-hydroxysteroid dehydrogenase type I (173-HSD I), which converts estrone produced by aromatase to estradiol, a biologically active estrogen and ER. Aromatase and 17p-HSD I immunoreactivity were both detected in smooth muscle cells (SMC) of the media in all the cases and in endothelial cells (EC) in 20 and 22 cases, respectively. ER immunoreactivity was detected in SMC of vena cava in 21 cases. The amount of aromatase mRNA was significantly greater in the cases utilizing is (I.3) or id (P.11) of exon 1 (9 cases, 191.1 ±26.3 attomol/ng total RNA) than those utilizing l b (1.4) as the promoter (14 cases, 50.6± 13.0 attomol/ng total RNA) (p < 0.01). Significant correlation (p < 6.05) was observed between the amount of aromatase mRNA and aromatase activity in 15 cases examined. No significant correlation was detected between the amount of aromatase mRNA or aromatase labeling index and the ER status. These results suggest that estrone and estradiol are produced in the human vena cava and that their production is mediated by aromatase and 17,0-HSD I, respectively but not all of these locally synthesized estrogens may not work directly in situ. In postmenopausal women and men, estrogen biosynthesis is mainly peripheral, through conversion of androstenedione or C19 steroids from the adrenal cortex, ovary and/or testis [7]. This conversion is catalyzed by the enzyme complex cytochrome P450 aromatase.
VARIOUS clinical and epidemiological observations suggest that sex steroids play an important role in the function and pathology of human veins [1] [2] [3] . Karas et al. recently demonstrated the presence of estrogen receptor (ER) in smooth muscle cells cultured from surgical specimens of non-pathological human saphenous veins removed for coronary artery bypass surgery [4] . Perrot-Applanat et al. also demonstrated the presence of progesterone receptor (PR) in varicose saphenous veins from both males and females. These results indicate that sex steroids may act directly on human veins, as reported in human coronary [5] and uterine arteries [6] .
In postmenopausal women and men, estrogen biosynthesis is mainly peripheral, through conversion of androstenedione or C19 steroids from the adrenal cortex, ovary and/or testis [7] . This conversion is catalyzed by the enzyme complex cytochrome P450 aromatase.
In humans, aromatase has been detected in numerous extragonadal tissues including adipocytes [8] , skin fibroblasts [9] , liver [10], brain [11] , bone [12] and various sex steroid-dependent neoplasms [13, 14, 15] . These estrogens derived from the local aromatization have been postulated to exert estrogenic actions on these tissues. Especially in sex-steroid dependent neoplasms, increased aromatase expression and/or activity in the tumor tissue has been demonstrated to closely correlate with malignant phenotype despite the fact that increased serum estrogen concentration has not been demonstrated in women with these tumors. In vascular tissues, aromatase activity has been demonstrated in cultured rat aortic endothelial cells (ECs) [17] and bovine aortic smooth muscle cells (SMCs) [18] but not in human vascular systems. In addition, localization of aromatase expression has not been studied in any species. Recently, alternative splicing of multiple forms of exon 1 has been demonstrated to contribute to the tissue-specific expression of aromatase [16, 19] . In addition, a frequent switching of tissue-specific exon is from exon lb or 1.4 to lc or 1.3 has been demonstrated for transcripts found in adipose tissues taken from breast cancer patients. This switching has been considered to result in overproduction of estrogens in situ and the subsequent proliferation of estrogen-dependent breast cancer cells [20, 21] . It therefore becomes very important to study the expression of aromatase and ER in situ, examine the utilization of exon is of aromatase and to correlate these findings in human veins, in order to understand the possible roles and biological significance of in situ estrogen production and possible direct effects of estrogen in the human vein.
Therefore, in this study we immunolocalized aromatase, semiquantitated the amount of aromatase mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR), and examined alternative splicing of multiple exons 1 in 29 cases of normal human vena cava obtained at autopsy. We also studied aromatase activity by 3H-water assay in 15 cases and immunolocalized ER and type I 17 beta-hydroxysteroid dehydrogenase (17j9-HSD I), which converts estrone (E1), the major product of aromatase, to estradiol (E2) [22] , a potent estrogen. 
63.6±3.0 year old

Semiquantitaion of immunoreactivity
We examined tissue sections under a light microscope and determined the labeling index as the ratio of positive vascular wall cells in order to semiquantitate immunoreactivity.
The immunostained slides were independently reviewed by two of the authors (H. Murakami and H. Sasano). Based on the percentage of cells that stained positive for aromatase, tissue slides were classified into four groups: -) none, l)1 to 5 %, 2) 5 to 25%, 3) 25%, according to the report of Watanabe et al. [27] with some modification. Disconcordant cases reported by these two investigators were re-evaluated simultaneously by Murakami and Sasano by means of double light microscopy.
with a specific sense primer labeled with a fluorescent dye and a specific antisense primer as previously described [15, 28] . The internal standard RNA used in the assays was synthesized in vitro from modified aromatase cDNA with 0.01 attomole of human aromatase RNA containing a 21-base insertion as an internal standard and amplified by PCR for 26 cycles with a fluorescent dye (FAM)-labeled
primer. An FAM-labeled sense primer (5' TACTACAACCGG-GTATATGG-3') corresponding to the sequence in exon 3 and an antisense primer (5'-TGTTAGAGG-TGTCCAGCATG-3') corresponding to the sequence in exon 5 were used in the PCR for quantitative analysis of aromatase mRNA.
An aliquot (4 tcl) of the fluorescent PCR products was mixed with 3 pl of GENESCAN-1000 ROX consisting of DNA size markers labeled with a fluorescent dye, ROX, and analyzed fluorometrically with a Gene Scanner 362
(Applied Biosystems). The FAM-labeled PCR products showed two peaks corresponding to PCR products of aromatase mRNA and the internal standard RNA at positions of approximately 378 and 399 bp, respectively.
These two peaks were designated AROM mRNA and standard RNA, respectively (Fig.  1A) . The internal size standards gave five peaks of 262, 293, 317, 439 and 557 as shown in Fig. 1A . The amount of aromatase mRNA in the tissue RNA was calculated from the peak areas of fluorescent products by the internal standard as previously described [28] . No fluorescent products were detected without adding RNA.
Utilization of Alternative Exons 1 Quantitative Analysis of Aromatase mRNA by PCR
The methods have been previously described by the authors [14, 15, 28] . Briefly, samples were homogenized in 5 volumes of 5 mol/L guanidine thiocyanate containing 5 mmol/L sodium citrate and 0.5% sodium sarcosyl. The total RNA fraction from all homogenates was prepared as described by Chirgwin et al. [29] . In all specimens examined, two distinctive bands corresponding to 285 and 18S of ribosomal RNA, were detected by running total RNA on an ethidium bromide stained agarose gel. In addition, a smear of mRNA was detected at 1 to 3 Kb in the gel. The measurement of aromatase mRNA in these samples was performed by RT-PCR The utilization of alternative exons 1 of the aromatase gene was examined by RT-PCR of the RNA fraction with sense primers specific for exons l b (I.4), l c (I.3) and l d (P.II) and the fluorescent dye-labeled antisense primer specific for exon 2 as described previously [14, 15, 28] . Harada et al. previously reported that exons la (I.1), lb (I.4), lc (I.3) and Id (P.II) are utilized in aromatase expression in human placenta, skin fibroblasts and fetal liver, ovary, prostate and brain, respectively. Exon 1 a was not examined in this study because exon 1 a is utilized exclusively in human placenta [281. Fluorescent PCR products were analyzed with a 362 Gene Scanner. The aromatase mRNAs transcribed from exons la (I.1), lb (I.4), lc (I.3) andld (P.II) SASANO et al. yielded PCR products at positions corresponding to 402, 327, 368 and 355 bp, respectively.
The Genescan-1000 ROX was used as internal size standard as in quantitative analysis of aromatase mRNA (Fig. 1B) .
Aromatase activity
Aromatase activity in human vena cava tissues was determined in 15 cases in which specimens were available according to the published method [30, 311 with modification. Microsomal fractions were prepared from vascular tissue homogenates by successive centrifugation as described [23] and suspended in 20 mmol/L Tris-HC1 (pH 7.5) containing 1 mmol/L EDTA, 10% glycerol, 5 mg/ml pepstatin and 5 mg/ml leupeptin. The reaction mixture comprised 0.1-1 mg of microsomal fraction, 5 mmol/L MgC12, 5 mmol/L glucose-6-phosphate, 5 units of glucose-6-phosphate dehydrogenase, 2 mmol/L rotenone and 200 pmol of lb-[3H] androstenedione (Dupont NEN) in 0.5 ml of 50 mmol/L Tris-HC1 (pH 7.5). After a Fig. 1 . An example of an analysis of a RT-PCR study of aromatase mRNA content (A) and utilization of alternative exon 1 (B) in inferior vena cava of case 9 in Table 1 (66-year-old female) by Gene Scanner 362. Peaks represent the Gene Scan 1000 ROX of the internal size standards, 261, 293, 317, 439 and 553 base pairs, respectively. (A) Peaks I and II represents PCR products of aromatase mRNA and the internal standard RNA at positions of 378 and 399 base pairs, respectively. In this case, mRNA content was calculated as 456.6 attomole per ng total RNA. (B) A major transcript of this case was exon id or P.II, which has a 355 by (base pair) with a minor transcript of exon lb or 1.4 (327 bp) and lc or 1.3 (368 bp) AND  SEX STEROID  RECEPTORS  IN HUMAN  VENA  CAVA   237 3 minute preincubation, the reaction was initiated by the addition of NADPH (0.5 mmol) and carried out for 60 minutes at 37°C. Under these conditions, the aromatase activity was linearly correlated with the amount of microsomal protein and the incubation time. The reaction was terminated by adding 3 ml of ice-cold chloroform, followed by vigorous vortexing and brief centrifugation. The resulting aqueous layer was further extracted with 3 ml of chloroform and then treated with 0.5 ml of 5% activated charcoal/0.5% dextran. After centrifugation of the mixture, the radioactivity of the supernatant was counted. Aromatase activity was quantified by measurement of the tritiated water released from lb-
The reaction was also performed in the presence of 10 mmol/L vorozole, a specific aromatase inhibitor, as a specificity control, and without NADPH as a background control. [30, 31] Statistical Analysis Aromatase mRNA levels were adjusted to those per total RNA and expressed as attomol/ng total RNA. All data were presented as the mean ± SEM. For comparisons involving several groups, one way ANOVA was employed. For comparisons between two groups, we used unpaired t-test after Fisher's exact test. In order to examine the correlation of the two factors, the Spearman's correlation coefficient was used. A value of p <0.05 was considered statistically significant.
Results
The results are summarized in Table 1 .
Immunolocalization of aromatase and 17Q-HSD 1
Immunoreactivity of both aromatase and 17~-HSD I was detected in cytoplasms of smooth muscle cells of inferior vena cava wall positive for a-smooth muscle action ( Fig. 2A and B) . 20/29 and 22/29 cases also demonstrated aromatase and 17 j3-HSD I immunoreactivity, respectively, in endothelial cells positive for CD34 antigen. (Fig. 2A and B) . There was a significant correlation between aromatase and 1713-HSD I LI (p = 0.078). There were no significant differences in aromatase or 17 j3-HSD I labeling index between men and women. There was no correlation between age and the labeling index when evaluating the whole group or men and women separately.
Immunolocalization of ER
ER immunoreactivity was detected in the nuclei of smooth muscle cells of inferior vena cava wall in 21/29 cases (Fig. 2C) . Endothelial cells were immunohistochemically negative for ER. In 13 cases, more than 5% of the smooth muscle cells were immunohistochemically positive. There were no significant differences in ER LI among tissues taken from men and women. There were no correlations between age and the labeling index when evaluating the whole group or men and women separately. There were no significant correlations among aromatase, 17 j3-HSD I and ER LI in the cases examined.
Quantitation of aromatase mRNA
Aromatase mRNA could be detected in all the cases examined. The amount of aromatase mRNA varied widely among the subjects (101.5±25.5 attomol/ng total RNA). Tissues from female cases (108.7 ± 32.1 attomol/ng total RNA) tended to have higher levels of aromatase mRNA than those from the male cases (89.2 ± 44.1 attomol/ng total RNA) but the differences did not reach statistical significances.
No significant correlation was detected between the amounts of aromatase mRNA and the age of the patients, or the labeling indices of aromatase, 17j3-HSD I and ER.
Alternative utilization of multiple copies of exon 1 s Alternative utilization of multiple copies of exon 1 could be evaluated in 23/24 specimens. The sizes of PCR products were 327 bp, 308 bp. and 355 by for exons lb (I.4) , lc (I.3) and id (P.II), respectively. Results are summarized in Table 1 as the major transcripts (9 cases; 191.1 ± 26.3 attomol/ng total RNA) was significantly higher than the amount in the cases utilizing mainly exon lb {I.4} (14 cases; 50.6± 13.0 attomol/ng total RNA) {p <0.001}. In particular, two cases which utilized exon 1 d (P.II) as the major transcript (case #9, 66 year old female and case #20, 58 year old male) demonstrated highest amounts of aromatase mRNA (case 10 in Table 1 ) Aromatase and 17j9-HSD I immunoreactivity were observed both in smooth muscle cells and endothelial cells. ER nuclear immunoreactivity was detected in smooth muscle cells.
cases examined. The amount of aromatase activity varied widely among the subjects (416.12±415 pmol/hour/mg protein, 86.2-1488.1 pmol/hour/ mg protein) but there was a significant correlation between the amounts of aromatase mRNA and activity in these 15 cases examined.
Discussion
In our present study, aromatase and 17R-HSD I immunoreactivity was detected in both smooth muscle cells and endothelial cells of inferior vena cava. In addition, aromatase activity was also detected in these tissues. These results therefore indicated that estrone is produced as a result of aromatization and is then converted to estradiol, a potent estrogen in human vena cava. In men and postmenopausal women, circulating estrogens have been considered to be mainly derived from aromatization occurring in adipocytes [7, 8] but the vena cava and possibly other veins, may also be considered to be important sources of circulating estrogens because of their close proximity to circulation.
Direct effects of sex steroids on human veins have been postulated by a number of investigators [1, 2, 3, 4, 5, 6] . Karas et al. reported the presence of ER in smooth muscle cells of human saphenous vein, although at a low level [4] but Perrot-Applanat et al. reported that ER and its mRNA were undetectable in 80% of saphenous veins examined [6] . The results of our present study of the human vena cava revealed that ER immunoreactivity was detected in smooth muscle cells of vena cava in 21/29 cases but ER immunoreactivity can be demonstrated only by means of the antigen retrieval and catalyzed signal amplification method. In addition, there were no correlations between the amounts of aromatase mRNA expression or aromatase LI and ER LI. Therefore, estrone or estradiol produced in endothelial or smooth muscle cells of vena cava may not necessarily act directly on these cells in situ. Further investigations including the analysis of newly characterized estrogen receptor beta [32, 33] in human veins are necessary to clarify the possible direct actions of estrogens on human vena cava and veins.
Recently, the expression of aromatase in various human tissues has been reported to be regulated by different tissue-specific factors, chiefly alternative use of exon 1 and promoters [16, 19, 281 . The results of our present study demonstrated that human vena cava tissues utilized exon lb or 1.4 (fibroblast type), exon 1 c or 1.3 and exon 1 d or P.II (gonadal type). Switching of alternative exons 1 was proposed to result in increased aromatase expression, and possible overproduction of estrogen in situ, under the control of a new promoter [20, 21] . In our present study, the amounts of aromatase mRNA in the cases utilizing gonadal types of exon 1, i.e., lc (1.3) and id (P.II), were significantly higher than in those that used other exon l s. In particular, two cases utilizing exon id (P.fI) as the major transcript demonstrated the highest amounts of aromatase mRNA among the cases examined. These results demonstrated that the utilization of gonadal type exon 1 may also be involved in overproduction of aromatase in vena cava as reported in human breast carcinoma [20, 21] , but further studies are needed to clarify whether switching of exon 1 has occurred or the utilization of exon 1 in vena cava is genetically determined among these subjects examined. Serum estrogen levels were not available in any of the patients examined in this study because all were autopsy materials but it is interesting to postulate that individuals utilizing exon 1 c (1.3) and 1 d (P.II) may use these exon 1 s in sites other than the vena cava including adipocytes and subsequently result in relatively high levels of circulating estrogens for age or sex.
